Laurie Sobel, associate director for women’s health policy at KFF, moderated a panel discussion about the challenges associated with providing insurance coverage for the first FDA-approved oral contraceptive, Opill.
The patient groups say the insurer is cutting off access to important medications. The Tennessee Blues plans say many of the drugs that it excluded from coverage have zero utilization.
Two reports show that drug-related deaths are skyrocketing among people 65 years and older.
Experts expect more lawsuits challenging CMS’s authority to negotiate drug prices for Medicare Part D.
FDA has set an action date of March 31, 2024, for marnetegragene autotemcel to treat infants with a serious and often fatal immunodeficiency.
Lawsuit accuses the companies of using unlawful, unfair, and deceptive practices.
Antimicrobial stewardship programs are being implemented in a variety of settings to assist with the challenges associated with the management of infectious diseases. Here's a review of ASPs from the perspective of a formulary decision-maker.
The setback for GlaxoSmithKline comes amid a multicompany race to develop a vaccine against respiratory syncytial virus infections.
Escalating costs are hitting patients hard. CMS price negotiation and the $2,000 cap on Part D out-of-pocket expenses should benefit many patients with Medicare coverage.
Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.
This guidance discusses that individuals 12 years and older can receive the second dose of the Pfizer-BioNTech vaccine 3-8 weeks after the first. Additionally, the interval for those 18 years and older for Moderna is 4-8 weeks.
The recent study also found that Jardiance for patients with heart failure with preserved ejection fraction could be cost-effective if discounted by 29%.
Aetna, Cigna, Humana, United Healthcare — some of the largest providers of Medicare Advantage plans — have released updates to prescription drug programs.
Accountable care organizations (ACOs) use digital health to complement traditional resources.
The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
In a 10-year, follow-up study in patients vaccinated with Gardasil 9, no cases of HPV-related cancers or genital warts were seen.
Antimicrobial stewardship programs are being implemented in a variety of settings to assist with the challenges associated with the management of infectious diseases. Here's a review of ASPs from the perspective of a formulary decision-maker.
Recent study finds that Medicaid coverage for some of the first gene and cell therapies was at times delayed and not consistent with federal requirements.
This abstract at the American Society of Clinical Oncology (ASCO 2023) looked at the growing utilization of trastuzumab biosimilars over time in India.
The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.
The class action lawsuit against CVS Health, Caremark, and Aetna was announced earlier today.
Biosimilars have the potential to lower costs, but the adoption has been slower than expected, a recent study finds.
The Magellan Rx Management CEO is replacing Ken Paulus, who has held the top job at Prime since May 2019.
The supply of fentanyl, epinephrine injection, and heparin, however, have been impacted by the July 19 tornado at Pfizer's North Carolina facility.
Patients with overactive bladder taking this OAB drug did not experience an excess risk of CV events compared with other treatments.
FDA is re-examining the safety of a breakthrough Parkinson’s disease drug after reports of hundreds of deaths.
A large-scale observational study led by Columbia University researchers may offer new approach to studying diverse patient groups.
Novo Nordisk’s DEVOTE study reveals interesting findings.